Abstract
Clinical studies in humans have shown that pranoprofen is an active anti-inflammatory, antipyretic, analgesic agent which is well tolerated by asthmatic patients with minimal side effects. This study was performed in animals in order to confirm its clinical superiority. Pranoprofen (1 mg/kg, i.v.) inhibited the SRS-A related phase in passive anaphylactic bronchoconstriction in guinea pigs pretreated with mepyramine. In IgE-mediated rat passive peritoneal anaphylaxis, pranoprofen (0.01-1mg/rat, i.p.) inhibited the release of SRS-A and histamine dose-dependently. Pranoprofen also inhibited the production of a prostaglandin E2 like substance, but did not increase the SRS- (A) production from rat peritoneal leucocytes which phagocytize killed bacteria in vitro. On the other hand, indomethacin distinctly enhanced SRS- (A) related reactions in these models. These results indicate that the low adverse effects of pranoprofen seen in treating asthma may be related to its inability to potentiate SRS- (A) production.
